Dow Chemical Company, Plaintiff/cross-Appellant v. United States

226 F.3d 1334, 56 U.S.P.Q. 2d (BNA) 1014, 2000 U.S. App. LEXIS 22514
Court of Appeals for the Federal Circuit·Decided September 6, 2000·No. 97-5035, 97-5038·Published·Cited by 85 cases

Opinion

ARCHER, Senior Circuit Judge.

DECISION

The United States appeals the judgment of the United States Court of Federal Claims in favor of Dow Chemical Company (Dow) holding the United States liable for damages for patent infringement. Dow cross-appeals the amount of damages awarded. We affirm-in-part, reverse-in-part, vacate-in-part, and remand the case for further proceedings consistent with this opinion.

BACKGROUND

I. For many years the United States Bureau of Mines (government) sought solutions to the problem of subsidence of the land overlying depleted mines. In the early 1970s Dow developed an improved method for filling abandoned mines in order to prevent the collapse of the overlying land.

In 1972, the government and Dow entered into a contract for subsidence control work at Scranton, Pennsylvania using the improved method. Under part of the contract, the government was licensed to use this invention as disclosed in U.S. Patent Application Serial No. 86,755 and any patents issuing thereon, including the patent-in-suit, U.S. Patent No. 3,817,039 (the ’039 patent). The terms of the license provided for (i) a royalty-free right to use the invention for government purposes on federal lands only; (ii) a royalty-free right to use the invention for government purposes to cover up to 2.5 million cubic feet of mine filling material on other than federal land; *1337 and (iii) thereafter, to use the invention at a royalty rate that would not exceed 25% of a reasonable commercial rate to • be agreed upon by the parties. After Dow completed the Scranton project, the government undertook an extensive program of mine backfilling projects using other contractors.

By letter dated July 9, 1975, Dow requested an accounting from the government for royalties due under the license. It also proposed a royalty rate to the government of 2% (25% of a reasonable commercial royalty) of the contract price for any particular project where the invention was used. During the remainder of 1975 and 1976, the parties undertook negotiations concerning the reasonable commercial royalty to be applied. 1

On December 28, 1976, the government informed Dow that it had not practiced the invention covered by the ’039 patent and, for this reason, no royalty payments were due. Dow requested that the government reconsider its position, and over the next two years the government investigated the claim.

On November 2, 1978, the government informed Dow that it had reconsidered its position expressed in the December 28, 1976 letter and that new information raised “seriously litigable issues” as to validity and infringement, and viability of the license. The letter affirmed that no royalty payments would be made and concluded this was the government’s “final decision,” and that “[n]o action will be taken on any further requests for reconsideration of this matter.”

Dow filed for a reissue of the ’039 patent in February 1980, which the government opposed. At the conclusion of the proceedings, all allegations of invalidity were overcome and the original claims remained intact. Based on these events, Dow requested that the government reconsider its refusal to pay royalties. The government advised Dow in December 1982 that it saw “no reason to change its position.”

In January 1983, Dow commenced suit seeking a reasonable royalty for the government’s infringement of the ’039 patent. In the alternative, Dow sought damages for the government’s breach of the license. By letter dated January 10, 1985, Dow notified the government that it was terminating the license, effective as of the date of the breach of the contract or the date of the notice, whichever was legally earlier, because the government had failed to pay royalties.

II. The Court of Federal Claims issued a series of opinions. First it held that the ’039 patent was not invalid and was infringed by the government. 2 Thereafter, the court held that the government’s nonpayment of royalties and repudiation of the license constituted a material breach that warranted voiding the contract ab ini-tio. For this reason damages were awarded on the basis of unlicensed infringement, instead of breach of contract. 3 The court also concluded that Dow’s infringement claim was not barred by the six year statute of limitations in 28 U.S.C. § 2501 due to the application of the tolling provisions of 35 U.S.C. § 286. 4 Finally, the court determined that the damages to Dow should be based on the value of the property saved (benefit conferred) rather than on the cost of projects using the invention. 5

*1338 The government now appeals the Court of Federal Claim’s judgment as to validity 6 and infringement of the patent.- It also appeals the court’s judgment that the license was void ab initio, and the court’s methodology for assessing damages. Dow cross-appeals the amount of the court’s damage award. We have jurisdiction to hear the appeal under 28 U.S.C. § 1295(a)(4)(A) (1994).

DISCUSSION

I.Infringement

“An infringement analysis entails two steps. The first step is determining the meaning and scope of the patent claims asserted to be infringed. The second step is comparing the properly construed claims to the device [or process] accused of infringing.” Markman v. Westview Instruments, Inc., 52 F.3d 967, 976, 34 USPQ2d 1321, 1326 (Fed.Cir.1995) (en banc), aff'd, 517 U.S. 370, 116 S.Ct. 1384, 134 L.Ed.2d 577, 38 USPQ2d 1461 (1996). The first step, claim construction, is a question of law which we review de novo. See Cybor Corp. v. FAS Techs., Inc., 138 F.3d 1448, 1456, 46 USPQ2d 1169, 1174 (Fed.Cir.1998) (en banc). Although we review claim construction de novo, “we ... begin with and carefully consider the trial court’s work.” Key Pharm. v. Hercon Labs. Corp., 161 F.3d 709, 713, 48 USPQ2d 1911, 1914 (Fed.Cir.1999) (citing Cybor, 138 F.3d at 1462-63, 46 USPQ2d at 1179-81 (Plager and Bryson, JJ., concurring separately)). The second step is a factual determination. See North Am. Vaccine, Inc. v. American Cyanamid Co.,

Free access — add to your briefcase to read the full text and ask questions with AI

Dow Chemical Company, Plaintiff/cross-Appellant v. United States, 226 F.3d 1334, 56 U.S.P.Q. 2d (BNA) 1014, 2000 U.S. App. LEXIS 22514 (Fed. Cir. 2000).

226 F.3d 1334 (Dow Chemical Company, Plaintiff/cross-Appellant v. United States) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related